Ichnos Sciences named Gabriela Gruia as its chief development officer. Gruia was most recently senior vice president and head of regulatory affairs for the Novartis (NYSE: [[ticker:NVS]]) oncology business. Her experience includes previous roles at Pharmacia and Pfizer (NYSE: [[ticker:PFE]]).
The Paramus, NJ, company is a spinout of Indian company Glenmark Pharmaceuticals that debuted in October with a pipeline of clinical-stage drug candidates.
Author: Sarah de Crescenzo
Sarah is Xconomy's San Diego-based editor. Prior to joining the team in 2018, she wrote about startups, tech and finance at the San Diego Business Journal. Her decade of full-time news experience includes coverage of subjects including campaign finance, crime and courts as a reporter and editor at outlets throughout California, including the Orange County Register.
She earned a bachelor's degree in English Literature at UC San Diego, where she wrote for the student newspaper and played collegiate lacrosse. In 2019, she earned an MBA at UC Irvine.
View all posts by Sarah de Crescenzo
